Redeye provides its initial take on Genovis’ Q3 2022 report, which came in just below our expectations on sales but significantly above our EBIT estimate. The impact of the COVID-19 pandemic is easing, and Genovis saw growth in all geographic markets. We consider this a strong report from Genovis.
Lähde: Finwire News
Genovis AB provides enzymes and technologies for analytical characterization and conjugation of biopharmaceuticals. The principal activities of the company are to develop, produce and market tools for developing new drugs and diagnostics. The Genovis product line comprises of GingisREX, FabRICATOR, GlyCLICK, GingisKHAN, GlycINATOR, Fabulous, lgGZERO, and Enzymes for O-glycan. The company serves mainly the medical device and pharmaceutical industries.